MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Investor Presentation (October 2018)
19 slides from MabVax Therapeutics's investor presentation, Oct 22, 2018
Slide 1: Novel Therapeutic Antibody for the Prevention and Treatment of Pancreatitis
M MabVax therapeutics Novel Therapeutic Antibody for the Prevention and Treatment of Pancreatitis * Building upon a unique insight into the fundamental biology of pancreatitis * Uniquely positioned to move into a phase 2 POC
Slide 2: Forward Looking Statements
Forward Looking Statements + MabVax Therapeutics Holdings, Inc. (the “Company") files annual, quarterly and other reports with the Securities and Exchange Commission (the "SEC") including its Annual Report on Form 10-K for the year ended December 31, 2017 (the “Form 10-K") which was filed on April 2
Slide 3: MabVax Company Background
MabVax Company Background Proprietary Approach to the Discovery and Development of Novel Fully Human Antibodies as Therapeutic and Diagnostic Agents Focused Discovery Fully human antibod response to the target antigen
Slide 4: Company Long Term Partnerships Result in Value Creation
Company Long Term Partnerships Result in Value Creation Discovery & Development Ongoing Partnerships With Recent Revenue Generating Platform Premier Research Institution Corporate Transactions Human antibody discovery platform | | * Memorial Sloan Kettering Cancer June 2018 - Neuroblastoma thas yiel
Slide 5: Overcoming Corporate Challenges for a Successful 2018
Overcoming Corporate Challenges for a Successful 2018 Challenges Faced in 2018 Actions Taken With Positive Outcomes Investor misconduct led to our delisting and caused us |__| Our corrective actions have remedied uncertainty ‘not to be current in SEC reporting about our capitalization and brought us
Slide 6: R&D Progress Continues Despite Challenging 2018
R&D Progress Continues Despite Challenging 2018 ‘Ongoing Research In: jon Collaborations Achieved Significant Progress Technology Validation and Continued Value Creation for Investors ‘Memorial Sloan Kettering Cancer Center + RO1 (NIH) funds 581 immunoPET Phase 1b (MVT- 2163) + UO1 (NIH) funds pre-t
Slide 7: Pancreatitis Market Opportunity: Critical Unmet Medical Need
Pancreatitis Market Opportunity: Critical Unmet Medical Need * Acute and Chronic pancreatitis drives 361,000? hospitalizations annually in the US * 275,000" for acute and 86,000? for chronic disease * Direct medical costs exceed $3.18*? annually *+ Approximately 20% of acute pancreatitis classified
Slide 8: Attractive Commercial Opportunity to Treat Pancreatitis
Attractive Commercial Opportunity to Treat Pancreatitis Significant Costs for Treatment __ Opportunities for cost savings _Significant Annual Treatment Population Tete Pancreatitis Reduction n morality |x. * Hospitalization LOS = Ave. 7 days Reduction in hospital 1S or in Ge |S * Cos $9,000 to $18,0
Slide 9: Discovery In Dr. David Tuveson's Lab at Cold Spring Harbor Laboratory
Discovery In Dr. David Tuveson’s Lab at Cold Spring Harbor Laboratory * Introduction through Vice Chair of Radiology at MSKCC Dr. Jason Lewis * Dr. Tuveson serves as Director of the Cold Spring Harbor Laboratory Cancer Center and the Chief Scientist for the Lustgarten Foundation * The Tuveson lab in
Slide 10: Clinical Implications of Inducible Expression of CA19-9
Clinical Implications of Inducible Expression of CA19-9 in Mice as a Tool to Study Pancreatitis CA19-9 is a promising new target for the treatment of pancreatitis + CA19-9 is an established serological clinical biomarker routinely used as a prognostic indicator of PDAC disease progression; CA19-9 is
Slide 11: CA19-9 Expression Induces Histologic Signs of Pancreatitis in Genetically Engineered Mouse Models
CA19-9 Expression Induces Histologic Signs of Pancreatitis in Genetically Engineered Mouse Models . Dayson Genetic Genetic._—-«Genetic_-—«Genetic Non-pancreatic tissues exhibited 1 normal histology relative to ag genetically negative littermate Controls following Dox time-course {All models demonstr
Slide 12: CA19-9 Expression in Mice Promotes Pancreatic Enzyme Elevation in Plasma
CA19-9 Expression in Mice Promotes Pancreatic Enzyme Elevation in Plasma ted histological signs of chronic pancreatitis, + Time dependent progression of disease state by continued dox induction + Elevated amylase, lipase and CA19-9 levels aligned with histopathology + Day 28 showed significant signs
Slide 13: CA19-9 Expression Induces Recruitment of Inflammatory Monocytes
CA19-9 Expression Induces Recruitment of Inflammatory Monocytes The percentage of immune cell types present in the pancreas quantified by flow cytometry (FB;LSL;PDX) Inflammatory Monocytes Engle et al. cancer Research 7830 ‘Supplement):A27-A27 + May 2018,
Slide 14: MVT-5873 Is Currently Active In Three Clinical Trials
MVT-5873 Is Currently Active In Three Clinical Trials MVT-5873 Prior Human Experience in Pancreatic Cancer and CA19-9 Positive Cancers * Safety established in over 50 subjects in 3 Phase 1 investigations ¥ NCT02672917 (MVTS873), NCTO2687230 (MVT-2163), NCTO3118349 (MVT-1075) + Monotherapy in late st
Slide 15: Clinical Plan: Severe Acute Pancreatitis
Clinical Plan: Severe Acute Pancreatitis Intent to treat population: Moderate to Severe Acute Pancreatitis (SAP) * Utilizes well established patient assessment to identify candidate patients + Typically within 24 hours of admission for pancreatitis + Treatment initiated as soon as SAP diagnosis is c
Slide 16: Development Plan to End of Phase 2
Development Plan to End of Phase 2 4Q.2018 10201: 20201: 3020: 4Q 2019 * Working to establish + File IND with FDA * First patients enrolled + Early assessment of > Gimatinteatintd KOL network + IRB Submission and * Expand enrollment to first subjects “+ Finalize clinical Review additonal sites + Gor
Slide 17: Two-Year Expense Plan To Reach End of Phase 2
Two-Year Expense Plan To Reach End of Phase 2 Top Line Summary of Expense Forecast a "I ar Fone
Slide 18: Unique Opportunity To Capitalize On Fundamental Discoveries Addressing Pancreatitis
Unique Opportunity To Capitalize On Fundamental Discoveries Addressing Pancreat MVT-5873 a Potential Pharmacological Agent to Improve Patient Care and Reduce Medical Costs * Significant unmet medical need with few if any therapeutic options * Groundbreaking work at CSHL reveals for first time key bi
Slide 19: For Further Information Please Contact
Mi MabVax therapeutics For Further Information Please Contact MabVax Therapeutics Holdings, Inc 11535 Sorrento Valley Road, Suite 400 ‘San Diego, CA 92121 David Hansen, CEO 858-500-8455 Greg Hanson,CFO 858-500-8457 Paul Maffuid, Exec. VP 858-500-8459
MabVax Therapeutics Holdings — Investor Presentation (October 2018) on 6ix